Recommendations for antibiotic selection for severe nosocomial infections
- PMID: 34693705
- PMCID: PMC8638841
- DOI: 10.37201/req/126.2021
Recommendations for antibiotic selection for severe nosocomial infections
Abstract
Severe infection and its evolution to sepsis are becoming more prevalent every day and are among the leading causes of critical illness and mortality. Proper management is crucial to improve prognosis. This document addresses three essential points that have a significant impact on this objective: a) early recognition of patients with sepsis criteria, b) identification of those patients who suffer from an infection and have a high risk of progressing to sepsis, and c) adequate selection and optimization of the initial antimicrobial treatment.
La infección grave y su evolución a sepsis son cada vez más frecuentes y se encuentran entre las principales causas de enfermedad crítica y mortalidad. El manejo adecuado es crucial para mejorar el pronóstico. Este documento desarrolla tres puntos esenciales que tienen un impacto significativo en este objetivo: a) el reconocimiento temprano de los pacientes que cumplen los criterios de sepsis, b) la identificación de aquellos pacientes que sufren una infección y tienen un alto riesgo de progresar a sepsis, y c) realizar una correcta elección y optimización del tratamiento antimicrobiano inicial.
Keywords: antimicrobial treatment; ceftazidime-avibactam; ceftolozane-tazobactam; meropenem; optimization; sepsis; septic shock; severe infection.
©The Author 2021. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
Conflict of interest statement
RSG, JM, and RA have received honoraria for lectures and advisory boards from Pfizer. JP has received honoraria for lectures from Pfizer, MSD, Shionogi and Menarini and for advisory boards Pfizer, Shionogi, and Menarini. MS has received honoraria for lectures and advisory boards from Pfizer, MSD, Gilead, Angelini and Janssen. AE has received honoraria for lectures and advisory boards from Pfizer, Gilead, MSD and Shionogi. JP has received honoraria for lec tures from Pfizer, MSD, Angelini, Astellas, Advanz and Menarini. AS, has received honoraria for lectures and advisory boards from Pfizer, MSD, Angelini, Shionogi, Menarini and Gilead. Rest of authors declare no conflict of interest.
Figures
References
-
- Fleischmann C, Scherag A, Adhikari NKJ, Hartog CS, Tsaganos T, Schlattmann P, et al. . Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am J Respir Crit Care Med. 2016;193:259–72. - PubMed
-
- Vincent J-L, Marshall JC, Namendys-Silva SA, François B, Martin-Loeches I, Lipman J, et al. . Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. Lancet Respir Med. 2014;2:380–6. - PubMed
-
- Raith EP, Udy AA, Bailey M, McGloughlin S, MacIsaac C, Bellomo R, et al. . Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care Unit. JAMA. 2017;317:290–300. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
